Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1981 Jul;68(1):13–20. doi: 10.1172/JCI110228

Corticosteroids block binding of chemotactic peptide to its receptor on granulocytes and cause disaggregation of granulocyte aggregates in vitro.

K M Skubitz, P R Craddock, D E Hammerschmidt, J T August
PMCID: PMC370767  PMID: 7251857

Abstract

Inhibition of complement-mediated granulocyte aggregation has recently been proposed as a mechanism of action of high-dose corticosteroids in shock states. Postulating that such inhibition might be effected through alteration of receptors function, we examined the effect of methylprednisolone (MP), hydrocortisone (HC), and dexamethasone (DEX) on the extent and kinetics of binding of the synthetic chemotaxin f-methionine-leucine-phenylalanine (FMLP) to its specific receptor on the granulocyte surface. Dose-dependent inhibition of binding was observed at corticosteroid concentrations paralleling plasma levels achieved with 30 mg/kg intravenous bolus therapy; the order of potency was MP greater than HC greater than DEX. Receptor number was unaffected by steroid exposure, but the steroids effected a decrease in association rate constant for the FMLP-receptor interaction (35% of N for 0.2 mg/ml MP), leading to decreased receptor-ligand affinity. Dissociation kinetics, as examined by cold-chase experiments, were unaltered by the corticosteroids. Furthermore, in addition to the inhibition of aggregation previously reported, aggregated granulocytes were found to disaggregate upon addition of corticosteroids; the order of potency was again MP greater than HC greater than DEX, with an MP concentration of approximately 2-3 mg/ml required to effect complete disaggregation. We conclude that corticosteroids can displace FMLP from the granulocyte surface by slowing association while allowing dissociation to proceed; altered kinetics of receptor-FMLP interaction may explain both the inhibition of granulocyte aggregation and granulocyte disaggregation. If these observations also hold for physiologic stimuli (such as C5adesarginine, which behaves similarly with respect to aggregation, inhibition, and disaggregation), such kinetic changes may be important in the clinical effects of very high-dose corticosteroids such as are administered in shock.

Full text

PDF
13

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Atkinson J. P., Frank M. M. Complement-independent clearance of IgG-sensitized erythrocytes: inhibition by cortisone. Blood. 1974 Nov;44(5):629–637. [PubMed] [Google Scholar]
  2. Atkinson J. P., Schreiber A. D., Frank M. M. Effects of corticosteroids and splenectomy on the immune clearance and destruction of erythrocytes. J Clin Invest. 1973 Jun;52(6):1509–1517. doi: 10.1172/JCI107325. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Böyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand J Clin Lab Invest Suppl. 1968;97:77–89. [PubMed] [Google Scholar]
  4. Crabtree G. R., Munck A., Smith K. A. Glucocorticoids inhibit expression of Fc receptors on the human granulocytic cell line HL-60. Nature. 1979 May 24;279(5711):338–339. doi: 10.1038/279338a0. [DOI] [PubMed] [Google Scholar]
  5. Craddock P. R., Fehr J., Brigham K. L., Kronenberg R. S., Jacob H. S. Complement and leukocyte-mediated pulmonary dysfunction in hemodialysis. N Engl J Med. 1977 Apr 7;296(14):769–774. doi: 10.1056/NEJM197704072961401. [DOI] [PubMed] [Google Scholar]
  6. Craddock P. R., Fehr J., Dalmasso A. P., Brighan K. L., Jacob H. S. Hemodialysis leukopenia. Pulmonary vascular leukostasis resulting from complement activation by dialyzer cellophane membranes. J Clin Invest. 1977 May;59(5):879–888. doi: 10.1172/JCI108710. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Craddock P. R., Hammerschmidt D., White J. G., Dalmosso A. P., Jacob H. S. Complement (C5-a)-induced granulocyte aggregation in vitro. A possible mechanism of complement-mediated leukostasis and leukopenia. J Clin Invest. 1977 Jul;60(1):260–264. doi: 10.1172/JCI108763. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. EISEN H. N. EQUILIBRIUM DIALYSIS FOR MEASUREMENT OF ANTIBODY-HAPTEN AFFINITIES. Methods Med Res. 1964;10:106–114. [PubMed] [Google Scholar]
  9. Fine J., Palmerio C., Rutenburg S. New developments in therapy of refractory traumatic shock. Arch Surg. 1968 Feb;96(2):163–175. doi: 10.1001/archsurg.1968.01330200001001. [DOI] [PubMed] [Google Scholar]
  10. Greenberg C. S., Hammerschmidt D. E., Craddock P. R., Jacob H. S. Atheroma cholesterol activates complement and aggregates granulocytes: possible role in ischemic manifestations of atherosclerosis. Trans Assoc Am Physicians. 1979;92:130–135. [PubMed] [Google Scholar]
  11. Hammerschmidt D. E., Craddock P. R., McCullough F., Kronenberg R. S., Dalmasso A. P., Jacob H. S. Complement activation and pulmonary leukotasis during nylon fiber filtration leukapheresis. Blood. 1978 Apr;51(4):721–730. [PubMed] [Google Scholar]
  12. Hammerschmidt D. E., Harris P. D., Wayland J. H., Craddock P. R., Jacob H. S. Complement-induced granulocyte aggregation in vivo. Am J Pathol. 1981 Feb;102(2):146–150. [PMC free article] [PubMed] [Google Scholar]
  13. Hammerschmidt D. E., Weaver L. J., Hudson L. D., Craddock P. R., Jacob H. S. Association of complement activation and elevated plasma-C5a with adult respiratory distress syndrome. Pathophysiological relevance and possible prognostic value. Lancet. 1980 May 3;1(8175):947–949. doi: 10.1016/s0140-6736(80)91403-8. [DOI] [PubMed] [Google Scholar]
  14. Hammerschmidt D. E., White J. G., Craddock P. R., Jacob H. S. Corticosteroids inhibit complement-induced granulocyte aggregation. A possible mechanism for their efficacy in shock states. J Clin Invest. 1979 Apr;63(4):798–803. doi: 10.1172/JCI109365. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Hirata F., Schiffmann E., Venkatasubramanian K., Salomon D., Axelrod J. A phospholipase A2 inhibitory protein in rabbit neutrophils induced by glucocorticoids. Proc Natl Acad Sci U S A. 1980 May;77(5):2533–2536. doi: 10.1073/pnas.77.5.2533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Hohn D. C., Meyers A. J., Gherini S. T., Beckmann A., Markison R. E., Churg A. M. Production of acute pulmonary injury by leukocytes and activated complement. Surgery. 1980 Jul;88(1):48–58. [PubMed] [Google Scholar]
  17. Hunninghake G. W., Fauci A. S. Immunologic reactivity of the lung. III. Effects of corticosteroids on alveolar macrophage cytotoxic effector cell function. J Immunol. 1977 Jan;118(1):146–150. [PubMed] [Google Scholar]
  18. Klempner M. S., Gallin J. I. Inhibition of neutrophil Fc receptor function by cotricosteroids. Clin Exp Immunol. 1978 Oct;34(1):137–142. [PMC free article] [PubMed] [Google Scholar]
  19. Kusajima K., Wax S. T., Webb W. R. Effects of methylprednisolone on pulmonary microcirculation. Surg Gynecol Obstet. 1974 Jul;139(1):1–5. [PubMed] [Google Scholar]
  20. Lawrence D. K., Gill E. W. Structurally specific effects of some steroid anesthetics on spin-labeled liposomes. Mol Pharmacol. 1975 May;11(3):280–286. [PubMed] [Google Scholar]
  21. NISONOFF A., PRESSMAN D. Heterogeneity and average combining constants of antibodies from individual rabbits. J Immunol. 1958 Jun;80(6):417–428. [PubMed] [Google Scholar]
  22. Niedel J. E., Kahane I., Cuatrecasas P. Receptor-mediated internalization of fluorescent chemotactic peptide by human neutrophils. Science. 1979 Sep 28;205(4413):1412–1414. doi: 10.1126/science.472759. [DOI] [PubMed] [Google Scholar]
  23. Niedel J., Wilkinson S., Cuatrecasas P. Receptor-mediated uptake and degradation of 125I-chemotactic peptide by human neutrophils. J Biol Chem. 1979 Nov 10;254(21):10700–10706. [PubMed] [Google Scholar]
  24. O'Flaherty J. T., Craddock P. R., Jacob H. S. Mechanism of anti-complementary activity of corticosteroids in vivo: possible relevance in endotoxin shock. Proc Soc Exp Biol Med. 1977 Feb;154(2):206–209. doi: 10.3181/00379727-154-39638. [DOI] [PubMed] [Google Scholar]
  25. O'Flaherty J. T., Kreutzer D. L., Showell H. J., Vitkauskas G., Becker E. L., Ward P. A. Selective neutrophil desensitization to chemotactic factors. J Cell Biol. 1979 Mar;80(3):564–572. doi: 10.1083/jcb.80.3.564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  26. O'Flaherty J. T., Showell H. J., Ward P. A. Neutropenia induced by systemic infusion of chemotactic factors. J Immunol. 1977 May;118(5):1586–1589. [PubMed] [Google Scholar]
  27. Oredugba O., Mazumdar D. C., Meyer J. S., Lubowitz H. Pulse methylprednisolone therapy in idiopathic, rapidly progressive glomerulonephritis. Ann Intern Med. 1980 Apr;92(4):504–506. doi: 10.7326/0003-4819-92-4-504. [DOI] [PubMed] [Google Scholar]
  28. Sacks T., Moldow C. F., Craddock P. R., Bowers T. K., Jacob H. S. Oxygen radicals mediate endothelial cell damage by complement-stimulated granulocytes. An in vitro model of immune vascular damage. J Clin Invest. 1978 May;61(5):1161–1167. doi: 10.1172/JCI109031. [DOI] [PMC free article] [PubMed] [Google Scholar]
  29. Schlessinger J., Shechter Y., Willingham M. C., Pastan I. Direct visualization of binding, aggregation, and internalization of insulin and epidermal growth factor on living fibroblastic cells. Proc Natl Acad Sci U S A. 1978 Jun;75(6):2659–2663. doi: 10.1073/pnas.75.6.2659. [DOI] [PMC free article] [PubMed] [Google Scholar]
  30. Schreiber A. D., Herskovitz B. S., Goldwein M. Low-titer cold-hemagglutinin disease. Mechanism of hemolysis and response to corticosteroids. N Engl J Med. 1977 Jun 30;296(26):1490–1494. doi: 10.1056/NEJM197706302962602. [DOI] [PubMed] [Google Scholar]
  31. Schreiber A. D., Parsons J., McDermott P., Cooper R. A. Effect of corticosteroids on the human monocyte IgG and complement receptors. J Clin Invest. 1975 Nov;56(5):1189–1197. doi: 10.1172/JCI108196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  32. Schumer W. Steroids in the treatment of clinical septic shock. Ann Surg. 1976 Sep;184(3):333–341. doi: 10.1097/00000658-197609000-00011. [DOI] [PMC free article] [PubMed] [Google Scholar]
  33. Skubitz K. M., Craddock P. R. Reversal of hemodialysis granulocytopenia and pulmonary leukostasis: A clinical manifestation of selective down-regulation of granulocyte responses to C5adesarg. J Clin Invest. 1981 May;67(5):1383–1391. doi: 10.1172/JCI110166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Sladen A. Methylprednisolone. Pharmacologic doses in shock lung syndrome. J Thorac Cardiovasc Surg. 1976 May;71(5):800–806. [PubMed] [Google Scholar]
  35. Sneiderman C. A., Wilson J. W. Effects of corticosteroids on complement and the neutrophilic polymorphonuclear leukocyte. Transplant Proc. 1975 Mar;7(1):41–48. [PubMed] [Google Scholar]
  36. Sullivan S. J., Zigmond S. H. Chemotactic peptide receptor modulation in polymorphonuclear leukocytes. J Cell Biol. 1980 Jun;85(3):703–711. doi: 10.1083/jcb.85.3.703. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Tolone G., Bonasera L., Sajeva R. Effects of hydrocortisone on binding of IgG or C3b-coated erythrocytes to human monocytes and polymorphonuclear leucocytes. J Pharm Pharmacol. 1979 Aug;31(8):563–564. doi: 10.1111/j.2042-7158.1979.tb13588.x. [DOI] [PubMed] [Google Scholar]
  38. Vitkauskas G., Showell H. J., Becker E. L. Specific binding of synthetic chemotactic peptides to rabbit peritoneal neutrophils: effects on dissociability of bound peptide, receptor activity and subsequent biologic responsiveness (deactivation). Mol Immunol. 1980 Feb;17(2):171–180. doi: 10.1016/0161-5890(80)90069-3. [DOI] [PubMed] [Google Scholar]
  39. White G. L., Archer L. T., Beller B. K., Hinshaw L. B. Increased survival with methylprednisolone treatment in canine endotoxin shock. J Surg Res. 1978 Oct;25(4):357–364. doi: 10.1016/0022-4804(78)90131-2. [DOI] [PubMed] [Google Scholar]
  40. Williams A. F., Galfrè G., Milstein C. Analysis of cell surfaces by xenogeneic myeloma-hybrid antibodies: differentiation antigens of rat lymphocytes. Cell. 1977 Nov;12(3):663–673. doi: 10.1016/0092-8674(77)90266-5. [DOI] [PubMed] [Google Scholar]
  41. Williams L. T., Snyderman R., Pike M. C., Lefkowitz R. J. Specific receptor sites for chemotactic peptides on human polymorphonuclear leukocytes. Proc Natl Acad Sci U S A. 1977 Mar;74(3):1204–1208. doi: 10.1073/pnas.74.3.1204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  42. Wilson J. W. Treatment or prevention of pulmonary cellular damage with pharmacologic doses of corticosteroid. Surg Gynecol Obstet. 1972 Apr;134(4):675–681. [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES